More than 100 million U.S. adults are now living with diabetes or prediabetes, according to the Centers for Disease Control and Prevention (CDC). As of 2015, 30.3 million Americans – 9.4 percent of the U.S. population – have diabetes. Another 84.1 million have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years.

Early detection of cardiovascular and peripheral neuropathies is key to managing diabetic patient populations. We are proud to offer leading-edge Autonomic Nervous System testing solutions that enable physicians to detect and manage ANS conditions. Our equipment measures galvanic skin response and Heart Rate Variability through a simple, quick, and non-invasive test that gives providers the ability to detect autonomic neuropathy before it becomes symptomatic.

Peripheral and cardiovascular neuropathy are among the largest concerns for diabetic patients, and it has been repeatedly proven that the earlier this condition can be detected and treated, the more likely a patient is to live a long and healthy life. Current estimates put the likelihood that a diabetic patient showing physical symptoms of peripheral neuropathy will survive through the next five years at between only 25 and 50 percent. By catching this condition through regular testing, health care providers can make a positive difference.

Autonomic Nervous System testing requires only minutes to set up and operate – the benefits for your patients last a lifetime. Also, with insurance billing codes that work with major private insurance, including Medicare, you can be sure that this is one solution that truly benefits your practice as well.